SMX (Security Matters) Public Limited Company is a Dublin, Ireland-based provider of brand protection, authentication, and track-and-trace technology for the anti-counterfeit market. Its proprietary marker system embeds a permanent or removable molecular marker on solid, liquid, or gaseous materials, paired with a reader and connected to a blockchain digital platform. The technology supports applications across precious metals, critical minerals, energy, agriculture, textiles, electronics, and advanced manufacturing, as well as sustainability and circular-economy initiatives. The company serves brand owners, manufacturers, and suppliers. Formerly known as Empatan Public Limited Company, it adopted its current name in February 2023 and is led by founder and Chief Executive Officer Haggai Alon.
SMX operates in the Industrials sector within specialty business services and is listed on the Nasdaq Capital Market. Investors follow the stock for its exposure to supply-chain traceability and blockchain-verified authentication, but the company remains a speculative micro-cap with a market capitalization near $4 million, a thin public float, and a history of reverse stock splits. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the trailing 30 days, SMX fell from a closing price of approximately $9.97 to $4.65, a decline of roughly 53%. The move was not linear: the stock experienced a sharp single-day drop in mid-October, followed by renewed volatility in early November, when prices briefly spiked before giving back those gains.
The quarterly picture is even more pronounced. In mid-August, SMX traded around the mid-$40s. The roughly 90% slide since then reflects sustained selling pressure rather than a short-lived pullback, with the stock trending lower through September and October and touching a multi-week trough in early November.
The recent decline has been driven primarily by structural and balance-sheet factors rather than positive operating developments. The company has registered shares for sale through an equity line arrangement, as detailed in its September 2026 prospectus filings, which creates ongoing dilution risk for existing holders. A reverse stock split completed in November 2026, aimed at maintaining Nasdaq listing compliance, further underscored the pressure on the share price and contributed to outsized price swings.
Company filings continue to flag material risks, including a high level of indebtedness, substantial cash requirements, and the possibility that the securities could be delisted from Nasdaq. Regulatory and ownership filings in early November, including a Schedule 13G and a Form 6-K, arrived amid the sell-off. With a very low float and limited analyst coverage, these factors have translated into pronounced volatility and a negative beta, leaving the stock highly sensitive to supply-and-demand imbalances.
The broader multi-month decline reflects a company that has repeatedly relied on capital raises, share issuance, and reverse stock splits to fund operations and preserve its listing. Across 2025 and 2026, SMX completed multiple reverse splits, and a stockholder rights plan—often described as a “poison pill”—was adopted in February 2026. These moves point to a continuing need to manage share structure and control rather than to an improving fundamental trajectory.
Financially, the company has reported significant net losses and negative free cash flow, with a limited cash position relative to its spending. With no near-term path to profitability signaled and limited institutional sponsorship, the stock has repriced lower throughout the quarter as risk appetite for speculative micro-caps remained subdued.
Looking ahead, investors should monitor several factors. First, the company’s upcoming financial results and any guidance on cash runway, revenue progress, and cost discipline will be critical, given the persistent losses and negative free cash flow. Second, the pace of share issuance under the registered equity line will determine how much additional dilution existing holders may absorb. Third, Nasdaq listing status and any further reverse splits or compliance measures remain central risks.
Broader conditions also matter: demand for supply-chain traceability and blockchain-verified authentication, competitive pressures in the anti-counterfeit market, and overall sentiment toward speculative micro-cap names could all influence trading. Because analyst coverage is limited, price action may continue to be driven more by funding and listing developments than by fundamental milestones. The information above is provided for context and is not a recommendation to buy or sell any security.
In my analysis of high-volatility micro-caps like this one, I have found value in reviewing automated strategies through Tickeron’s AI Trading Bots. These resources allow me to evaluate systematic approaches across different risk profiles and timeframes without relying solely on manual chart work. The platform aggregates data from numerous strategies, helping highlight options that align with current market conditions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
Be on the lookout for a price bounce soon.
The Moving Average Convergence Divergence (MACD) for SMX just turned positive on October 15, 2026. Looking at past instances where SMX's MACD turned positive, the stock continued to rise in 19 of 33 cases over the following month. The odds of a continued upward trend are 58%.
SMX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +290.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where SMX advanced for three days, in 82 of 126 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
SMX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The 10-day RSI Indicator for SMX moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In 8 of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at 42%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SMX as a result. In 58 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SMX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for SMX entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.043) is normal, around the industry mean (5.887). P/E Ratio (-0.009) is within average values for comparable stocks, (33.618). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.946). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (9.907).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. SMX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SMX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry OfficeEquipmentSupplies